Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NIP-specific DNA vaccine
- Development stage
- Discontinued
- Lead developer
- Nykode Therapeutics
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intradermal
01
Overview
The NIP-specific DNA vaccine is an experimental DNA plasmid construct developed within the Vaccibody platform (now Nykode Therapeutics) to serve as a non-targeted negative control in immunotherapy research. It encodes a homodimeric fusion protein consisting of three functional modules: a targeting unit, a dimerization unit, and an antigenic unit. In this specific construct, the targeting unit is a single-chain variable fragment (scFv) specific for the synthetic hapten 5-iodo-4-hydroxy-3-nitrophenylacetyl (NIP). Because NIP is not naturally present in mammalian organisms, the secreted protein does not bind to any endogenous receptors, effectively acting as a non-targeted delivery system. This construct is used in preclinical studies, particularly for B-cell malignancies like chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), to establish a baseline for immune responses against tumor-specific idiotypes when compared to vaccines that actively target antigen-presenting cells (APCs) via MHC class II or chemokine receptors.
- Other names
- anti-NIP Vaccibodynon-targeted control DNA vaccineNIP-targeted Vaccibody control
02
Targets
CCR1CCR5 (C-C chemokine receptor type 5)
Beyond the preview
Go deeper on NIP-specific DNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NIP-specific DNA vaccine.